Not medical advice. GLP-1 RC-T is sold for research. This guide does not recommend dosing, diagnosis, or therapy.
GLP-1 RC-T combines GLP-1 and GIP activity in one molecule; papers highlight dual incretin mechanisms and metabolic endpoints in controlled studies.
One-paragraph overview from our research datasheet, still scientific, but faster to read than the full mechanism list below.
GLP-1 RC-T, dual GIP/GLP-1 receptor agonist with imbalanced agonism favouring GIP, with body-composition reductions reported in published research.
Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss, cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.
“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.
Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. - see our storage guide for best practices on temperature, light, and shelf life.
Typical research dosing discussion (literature-style): 2.5–15 mg subcutaneously (dose escalation) · Once weekly subcutaneous injection · t½ ≈ 5 days (116.7 h mean); Tmax = 8–72 h; Vd ≈ 10.3 L; 99% albumin bound; bioavailability ~80%; dose escalation: 2.5 mg × 4 wk → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. Metabolized via proteolytic cleavage, C20 diacid β-oxidation, and amide hydrolysis; ~66% renal / ~33% fecal elimination as metabolites.
For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes, and always verify batch purity by reading the COA.
Other compounds researchers often read about alongside GLP-1 RC-T.
What is GLP-1 RC-T in plain language?
GLP-1 RC-T is a research peptide we catalogue under “Metabolic / Fat Loss.” This article explains how scientists discuss it in published literature and what study types usually appear, not as a consumer product claim.
Does this page give medical advice or dosing instructions for GLP-1 RC-T?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.
Where can I see purity, variants, and pricing for GLP-1 RC-T?
Use the “View product” button to open the canonical shop listing for GLP-1 RC-T, where specifications and research SKU details are shown.
What about online case reports, before-and-after stories, or forum “logs” for GLP-1 RC-T?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.
Primary literature and registries for GLP-1 RC-T, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Open the shop listing for variants, purity notes, and research SKU details.
View productAlso known as: GLP-1 RC-T, GIP/GLP-1 Dual Agonist, Dual Incretin Agonist, Twincretin